BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Park HS, Cho U, Im SY, Yoo CY, Jung JH, Suh YJ, Choi HJ. Loss of Human Leukocyte Antigen Class I Expression Is Associated with Poor Prognosis in Patients with Advanced Breast Cancer. J Pathol Transl Med 2019;53:75-85. [PMID: 30424591 DOI: 10.4132/jptm.2018.10.11] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Emens LA, Adams S, Cimino-Mathews A, Disis ML, Gatti-Mays ME, Ho AY, Kalinsky K, McArthur HL, Mittendorf EA, Nanda R, Page DB, Rugo HS, Rubin KM, Soliman H, Spears PA, Tolaney SM, Litton JK. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. J Immunother Cancer 2021;9:e002597. [PMID: 34389617 DOI: 10.1136/jitc-2021-002597] [Reference Citation Analysis]
2 Weiss SA, Sznol M. Resistance mechanisms to checkpoint inhibitors. Curr Opin Immunol 2021;69:47-55. [PMID: 33676271 DOI: 10.1016/j.coi.2021.02.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Yu P, Zhu L, Cui K, Du Y, Zhang C, Ma W, Guo J. B4GALNT2 Gene Promotes Proliferation, and Invasiveness and Migration Abilities of Model Triple Negative Breast Cancer (TNBC) Cells by Interacting With HLA-B Protein. Front Oncol 2021;11:722828. [PMID: 34589428 DOI: 10.3389/fonc.2021.722828] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Tsang JY, Ho CS, Ni YB, Shao Y, Poon IK, Chan SK, Cheung SY, Shea KH, Marabi M, Tse GM. Co-expression of HLA-I loci improved prognostication in HER2+ breast cancers. Cancer Immunol Immunother 2020;69:799-811. [PMID: 32055918 DOI: 10.1007/s00262-020-02512-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Souza-Fonseca-Guimaraes F, Cursons J, Huntington ND. The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy. Trends Immunol 2019;40:142-58. [PMID: 30639050 DOI: 10.1016/j.it.2018.12.003] [Cited by in Crossref: 119] [Cited by in F6Publishing: 112] [Article Influence: 39.7] [Reference Citation Analysis]
6 Goldberg J, Pastorello RG, Vallius T, Davis J, Cui YX, Agudo J, Waks AG, Keenan T, McAllister SS, Tolaney SM, Mittendorf EA, Guerriero JL. The Immunology of Hormone Receptor Positive Breast Cancer. Front Immunol 2021;12:674192. [PMID: 34135901 DOI: 10.3389/fimmu.2021.674192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sadagopan A, Michelakos T, Boyiadzis G, Ferrone C, Ferrone S. Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors: A Review. JAMA Oncol 2021. [PMID: 34940799 DOI: 10.1001/jamaoncol.2021.5970] [Reference Citation Analysis]
8 Masterson L, Howard J, Gonzalez‐cruz J, Jackson C, Barnett C, Overton L, Liu H, Ladwa R, Simpson F, Mcgrath M, Wallwork B, Jones T, Ottensmeier C, Chua ML, Perry C, Khanna R, Panizza B, Porceddu S, Lechner M. Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation? Int J Cancer 2019;146:2305-14. [DOI: 10.1002/ijc.32869] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
9 Wei Y, Xiao X, Lao XM, Zheng L, Kuang DM. Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors. Cell Mol Life Sci 2021;78:867-87. [PMID: 32940722 DOI: 10.1007/s00018-020-03637-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Radosevic-Robin N, Selenica P, Zhu Y, Won HH, Berger MF, Ferrando L, Cocco E, Privat M, Ponelle-Chachuat F, Abrial C, Nabholtz JM, Penault-Llorca F, Reis-Filho JS, Scaltriti M. Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies. NPJ Breast Cancer 2021;7:124. [PMID: 34535679 DOI: 10.1038/s41523-021-00334-5] [Reference Citation Analysis]